Atea reports positive topline results in Phase III hepatitis C study

Phase 3positiveBEM/RZRPositive

AI Analysis

Summary

Atea Pharmaceuticals reported positive topline results from its Phase III C-BEYOND trial evaluating the once-daily fixed-dose BEM/RZR combination for chronic hepatitis C infection in North America.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Positive topline results from Phase III C-BEYOND trial

Importance:8/10

Sentiment:

0.85

Phase 3Hepatitis CPositive ResultsFixed-dose combinationOnce-daily

Related Companies

$AVIR

Read the original article

Published by Clinical Trials Arena on July 29, 2026 7:53 AM

Read Original